Article Text

other Versions

PDF
Genetically designing a more potent anti-pancreatic cancer agent by simultaneously cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
  1. Daniel A Vallera (valle001{at}umn.edu)
  1. University of Minnesota Cancer Center, United States
    1. Brad J Stish
    1. University of Minnesota Cancer Center, United States
      1. Yanqun Shu
      1. University of Minnesota Cancer Center, United States
        1. Hua Chen
        1. University of Minnesota Cancer Center, United States
          1. Ashok Saluja
          1. Department of Surgery, University of Minnesota Medical School, United States
            1. Donald J. Buchsbaum
            1. Department of Radiation Oncology, University of Alabama at Birmingham, United States
              1. Selwyn M. Vickers
              1. Department of Surgery, University of Minnesota Medical School, United States

                Abstract

                Objective: Investigators are currently interested in the EGFR and IL-13R as potential targets in the development of new biologicals for pancreatic cancer. Attempts to develop successful agents have met with difficulty. Our novel approach was to simultaneously target these receptors with EGF and IL-13 cloned on the same bispecific single chain molecule with truncated diphtheria toxin (DT390) to determine if co-targeting with DTEGF13 had any advantages.

                Design: Proliferation experiments were performed to measure the potency and selectivity of bispecific DTEGF13 and its monospecific counterparts against pancreatic cancer cell lines Panc-1 and MiaPaCa-2 in vitro. DTEGF13 was then administered intratumorally to nude mice with MiaPaCa-2 flank tumors to measure efficacy and toxicity (weight loss).

                Results: In vitro, bispecific DTEGF13 was 2,800-fold more toxic than monospecific DTEGF or DTIL13 against Panc-1. A similar enhancement was observed in vitro when MiaPaCa-2 pancreatic cancer cells or H2981-T3 lung adenocarcinoma cells were studied. DTEGF13 activity was blockable with recombinant EGF13. DTEGF13 was potent (IC50 = 0.00017 nM) against MiaPaCa-2, receptor specific, and significantly inhibited MiaPaCa-2 tumor in nude mice (p<0.008).

                Conclusions: In vitro studies show that the presence of both ligands on the same bispecific molecule is responsible for the superior activity of DTEGF13. Intratumoral administration showed that DTEGF13 was highly effective in checking aggressive tumor progression in mice. Lack of weight loss in these mice indicated that the drug was tolerated and a therapeutic index exists in an 'on target' model in which DTEGF13 is cross-reactive with native mouse receptors.

                • EGF
                • IL-13
                • carcinoma
                • cytotoxin
                • diphtheria toxin

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.